Search Results - addiction

6 Results Sort By:
Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction
This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein...
Published: 7/25/2024   |   Inventor(s): Noel Southall, Marc Ferrer-Alegre, Daniel Jansen, Mark Henderson, Xin Hu, David Kim, Juan Marugan
Keywords(s): ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Research Materials
Phantasmidine, a Nicotinic Receptor Agonist for the Treatment of Addiction and Neurological Disorders
The inventors have isolated and characterized an alkaloid, phantasmidine, from the skin of the Ecuadoran poison frog E. anthonyi. Phantasmidine is selective for beta4-containing receptor subtypes, unlike many nicotinic receptor agonists currently in development, which target beta2-containing receptor subtypes. This selectivity makes phantasmidine...
Published: 7/25/2024   |   Inventor(s): Richard Fitch
Keywords(s): ADDICTION, AGONIST, Alkaloid, Alzheimer disease 1, Alzheimer disease 3, Alzheimer disease 4, Alzheimer disease type 1, Alzheimer disease type 4, Alzheimer disease, familial, type 3, EPIBATIDINE, IBXXXX, IXXXXX, nAChR, NBXXXX, NC2XXX, NCXXXX, Neurological, neurological disease, nicotine, NICOTINIC, NXXXXX, Patent Category - Chemistry, Phantasmidine
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics
Novel hasubanan-based analgesics
There are three main medication alternatives for use in treating opioid addiction; methadone, buprenorphine, and naltrexone which can be used separately or in combination (e.g., buprenorphine and naltrexone). All three medications are FDA approved and can reduce opioid cravings helping to sever the ties between opioid use and situational/emotional triggers....
Published: 2/5/2024   |   Inventor(s): Thomas Keck, Gustavo Moura-Letts
Keywords(s): Addiction, Neurological disorders, Therapeutic
Category(s): Human Health Care > Therapeutics
Vaccine for the Treatment of Cocaine Addiction and Relapse
Cocaine is the second most trafficked illegal substance in the world with more than 756 metric tons seized every year from authorities. In the United States, over 35 million people over the age of 12 have reported using cocaine, while being the most frequent illegal drugs reported by emergency rooms. Its popularity is due to its highly addictive nature...
Published: 5/31/2024   |   Inventor(s): Thomas Keck, Christopher Lowry
Keywords(s): Addiction, Cocaine, Inflammation, PTSD, Vaccine
Category(s): Human Health Care > Therapeutics
Strategy to Design Nicotine Vaccines
Cigarette smoking causes a variety of diseases with high morbidities and mortality; however, the addictive properties of nicotine make quitting difficult. Nicotine molecules enter the brain within seconds after use and activate reward pathways, leading to dependence. Despite extensive efforts toward cessation interventions, smoking remains a major public...
Published: 2/23/2023   |   Inventor(s): Yung Chang, Sidney Hecht, Joseph Leal, Viswanath Arutla, Xiaowei Liu, Sriram Sokalingam
Keywords(s): Addiction, Hapten, Immunogenecity, Linkers, Nicotine
Category(s): Life Science (All LS Techs), Advanced Materials/Nanotechnology, Pharmaceuticals, Non-Cancer Therapeutics, Vaccines/Antimicrobials
A new serum-based diagnostic for the detection of substance abuse and other addictive disorders
The proposed technology is a novel approach to a serum biomarker for substance abuse disorder based on the positive correlation between plasma S100B protein levels and addiction. It is proposed that the expression levels of the S100B protein will serve as an indicator of the process of addiction and decision-making. The changes may be detectable in...
Published: 2/13/2024   |   Inventor(s): Venkat Venkataraman, Richard Jermyn, Robert Steer
Keywords(s): Addiction, Biomarkers, Diagnostics, Substance Abuse
Category(s): Human Health Care > Biomarkers, Diagnosis and Detection